Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes in a midphase trial, positioning the biotech to advance the ex-Novartis ...
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
I believe the most important mention from its pipeline would be that it is gearing up to report results from its phase 2b IMPACT study targeting these patients with MASH. One must ask, aren't ...
Last week's survey by the British Potato Council revealed that we prefer mash to chips. So is this good news for our health? Nutritionally speaking, both mash and chips are good sources of energy ...